Company
Orion Corporation
Orion Corporation has 36 drugs tracked on RxWires: 6 post-market, 4 in Phase 3, 5 in Phase 2, 6 in Phase 1/2, 14 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Polyethylene glycol 4000 | Post-Market | Constipation |
| Levosimendan | Post-Market | Heart Failure |
| Buventol® Easyhaler® 200 µg/inhalation dmDPI | Post-Market | Asthma |
| Dexmedetomidine | Post-Market | ICU Sedation |
| Levosimendan infusion | Post-Market | Coronary Artery Disease |
| Stalevo (levodopa/carbidopa/entacapone) | Post-Market | Idiopathic Parkinson's Disease |
| Xenon | Phase 3 | Coronary Artery Disease |
| Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh | Phase 3 | Asthma |
| Ibuprofen | Phase 3 | Pain |
| Diuretics | Phase 3 | Advanced Chronic Heart Failure |
| ORM-12741 | Phase 2 | Alzheimer's Disease |
| ODM-101 65mg Carbidopa | Phase 2 | Parkinson's Disease |
| ODM-109 | Phase 2 | Amyotrophic Lateral Sclerosis |
| Tasipimidine | Phase 2 | Insomnia |
| ABX464 | Phase 2 | Ulcerative Colitis |
| ODM-212 | Phase 1/2 | Mesothelioma |
| ODM-201 | Phase 1/2 | Prostate Cancer |
| ODM-209 | Phase 1/2 | Prostate Cancer Metastatic |
| ODM-216 | Phase 1/2 | Advanced Solid Tumors Cancer |
| ODM-208 | Phase 1/2 | Prostate Cancer Metastatic |
| ODM-204 | Phase 1/2 | Prostate Cancer |
| Seretide Diskus and charcoal | Phase 1 | Asthma |
| ODM103 | Phase 1 | Healthy |
| Budesonide/formoterol | Phase 1 | Asthma |
| ODM-104 | Phase 1 | CNS Disease |
| Charcoal and Budesonide/formoterol Easyhaler 320/9 microg | Phase 1 | Asthma |
| ODM-201 Tablet A | Phase 1 | Prostate Cancer |
| Tiotropium Bromide Monohydrate | Phase 1 | Healthy Subjects |
| Salmeterol/fluticasone Easyhaler | Phase 1 | Asthma |
| Atipamezole | Phase 1 | Healthy |
| salmeterol-fluticasone | Phase 1 | Asthma |
| 11C-ORM-13070 | Phase 1 | Healthy |
| levodopa, carbidopa, ODM-104 | Phase 1 | Parkinson's Disease |
| Budesonide/formoterol 320/9 μg and 400/12 μg inhalers | Phase 1 | Asthma |
| Alprazolam | Phase 1 | Healthy |
| Placebo Tiotropium inhalation powder type A | Not Applicable | Healthy Volunteer |
Latest
- Odm 212 moved to Phase 1/2
- orion corporation filed 8-K
- orion corporation filed 8-K
- orion corporation filed 8-K
- orion corporation filed 8-K
Follow Orion Corporation on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.